Hypertension Clinical Trial
Official title:
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ADX-850 in Participants With Hypertension
The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in patients with hypertension.
Status | Recruiting |
Enrollment | 72 |
Est. completion date | June 30, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Body mass index (BMI) between 18 and 35 kg/m2 - Body weight =55 kg - No use of antihypertensive medication for a minimum of 2 weeks or 5 half-lives - Access to and ability to use antihypertensive medication/access to emergency services to treat hyper- or hypotensive events - Contraception use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies - Willing and able to provide informed consent and comply with all study visits - Willing to start or switch to irbesartan as concomitant ARB therapy, if applicable (Part 2 only) Exclusion Criteria: - Any significant medical history - Secondary hypertension - Active malignancy and/or history of malignancy in the past 5 years - History of liver disease, Gilbert's syndrome, nonalcoholic steatohepatitis, severe steatosis, or abnormal liver function test - Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, red blood cell (RBC), hemoglobin, hematocrit, reticulocytes, gamma-glutamyl transferase (GGT), and creatinine must be within normal range at screening and prior to dosing - Any active infection or acute illness - Major surgery or significant traumatic injury occurring within 3 months - Any other conditions that, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study - Mean sitting diastolic BP (DBP) =110 mmHg at any time prior to randomization. - Orthostatic hypotension - eGFR <60 mL/min/1.73m2 - Abnormal potassium levels <3.5 and >5 mmol/L - History or presence of clinically significant ECG abnormalities and corrected QTcF >450 ms prior to dosing - Positive serology tests (HepB, Hep C, HIV) - Use of unapproved prescription, vaccines, supplements/vitamins, or over-the counter medication - Treatment with another investigational product concurrently or within 30 days prior to the first study drug administration - Known hypersensitivity to any of the study drug ingredients - Pregnancy, intent to become pregnant during the course of the study, or lactating women - History or presence of alcohol abuse - Night shift workers (regular working hours between 10:00 PM and 6:00 AM) - Known history of intolerance to ARB medication (Part 2 only) |
Country | Name | City | State |
---|---|---|---|
Australia | CMAX Clinical Research | Adelaide | South Australia |
Australia | Linear Clinical Research | Nedlands | Western Australia |
Lead Sponsor | Collaborator |
---|---|
ADARx Pharmaceuticals, Inc. | ADARx Australia Pty Ltd |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PART 1 - Safety in Patients with Hypertension | To evaluate the safety and tolerability of ADX-850 in hypertension patients by incidence, relationship, and severity of adverse events and serious adverse events | 365 days | |
Primary | PART 2 - Safety in Patients with Hypertension | To evaluate the safety and tolerability of ADX-850 in hypertension patients by incidence, relationship, and severity of adverse events, adverse events of special interest, and serious adverse events | 365 days | |
Secondary | PART 1 - Plasma Pharmacokinetics in Patients with Hypertension | To characterize the Pharmacokinetics of ADX-850 by measuring the Maximum Observed Concentration (Cmax) based on concentration in plasma | 8 days | |
Secondary | PART 1 - Plasma Pharmacokinetics in Patients with Hypertension | To characterize the Pharmacokinetics of ADX-850 by measuring the Dose-Normalized Maximum Observed Concentration (Cmax/D) based on concentration in plasma | 8 days | |
Secondary | PART 1 - Plasma Pharmacokinetics in Patients with Hypertension | To characterize the Pharmacokinetics of ADX-850 by measuring the Time to Maximum Observed Concentration (Tmax) based on concentration in plasma | 8 days | |
Secondary | PART 1 - Plasma Pharmacokinetics in Patients with Hypertension | To characterize the Pharmacokinetics of ADX-850 by measuring the Area Under the Concentration-Time Curve (AUC) based on concentration in plasma | 8 days | |
Secondary | PART 1 - Plasma Pharmacokinetics in Patients with Hypertension | To characterize the Pharmacokinetics of ADX-850 by measuring the Dose-Normalized Area Under the Concentration-Time Curve (AUC/D) based on concentration in plasma | 8 days | |
Secondary | PART 1 - Plasma Pharmacokinetics in Patients with Hypertension | To characterize the Pharmacokinetics of ADX-850 by measuring the terminal half-life (t½) based on concentration in plasma | 8 days | |
Secondary | PART 1 - Biomarker Activity in Patients with Hypertension | To characterize the change from baseline in plasma AGT concentration | 365 days | |
Secondary | PART 2 - Biomarker Activity in Patients with Hypertension | To characterize the change from baseline in plasma AGT concentration | 365 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |